Neurotrope, Inc. Common
NTRP
NTRP was delisted on the 1st of December, 2020.
24 hedge funds and large institutions have $12.5M invested in Neurotrope, Inc. Common in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 23 → 24 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $12.7M → $12.5M (-$209K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$293K |
| 2 |
Renaissance Technologies
New York
|
+$201K |
| 3 |
Millennium Management
New York
|
+$143K |
| 4 |
ISL
Ingalls & Snyder LLC
New York
|
+$125K |
| 5 |
CC
Cannell & Co
New York
|
+$95.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$80K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$7.66K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$4K |
| 4 |
BCA
Bay Colony Advisors
Concord,
Massachusetts
|
-$2K |
| 5 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$115 |
NTRP Hedge Fund Activity: Q3 2018 in Review
24 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Neurotrope, Inc. Common (NTRP) for Q3 2018, worth a combined $12.5M — down 1.6% from $12.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NTRP positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 2 trimmed.
The largest buyer was Pathstone Family Office, opening a new position worth an estimated $293K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $80K sold.
- 24 institutional investors held Neurotrope, Inc. Common (NTRP) as of Q3 2018, up from 23 in Q2 2018.
- Funds reported $12.5M of Neurotrope, Inc. Common stock for Q3 2018, down 1.6% quarter-over-quarter.
- 5 funds opened new Neurotrope, Inc. Common positions in Q3 2018 and 4 closed out, a net change of +1 holder.
- The largest Neurotrope, Inc. Common buyer in Q3 2018 was Pathstone Family Office, an estimated $293K added.
- The largest Neurotrope, Inc. Common seller in Q3 2018 was JP Morgan Chase, an estimated $80K sold.
Based on aggregated 13F filings for Q3 2018.